Article Information
- Received January 24, 2019
- Revision received May 13, 2019
- Accepted May 19, 2019
- Published online July 25, 2019.
Author Information
- A. C. Meirsman1,2,
- Sami Ben Hamida3,
- E. Clarke3,
- A. de Kerchove d’Exaerde4,
- E. Darcq3 and
- B. L. Kieffer3
- 1Département de Médecine Translationnelle et Neurogénétique, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Médicale Unité 964, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7104, Université de Strasbourg, Illkirch, France
- 2Neuroscience Paris Seine, Institut de Biologie Paris Seine, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8246/Institut National de la Santé et de la Recherche Médicale Unité 1130/Université Pierre et Marie Currie, Paris F-75005, France
- 3Douglas Research Center, Department of Psychiatry, McGill University, Montréal, Canada
- 4Laboratory of Neurophysiology, Université Libre de Bruxelles (ULB), ULB Neuroscience Institute, 1070 Brussels, Belgium
- Correspondence should be addressed to B.L. Kieffer at brigitte.kieffer{at}douglas.mcgill.ca
Author contributions
Author contributions: A.C.M., S.B.H., and B.L.K. designed research; A.C.M., S.B.H., E.C., and E.D. performed research; A.C.M., S.B.H., E.D., and B.L.K. analyzed data; A.C.M., S.B.H., A.d.K.d., E.D., and B.L.K. wrote the paper.
Disclosures
All authors declare no competing financial interests.
This work was supported by the National Institutes of Health National Institute of Drug Abuse Grant 05010 (to B.L.K.), the National Institute on Alcohol Abuse and Alcoholism Grant 16658 (to B.L.K.), the Canada Fund for Innovation and the Canada Research Chairs (B.L.K.), Fonds de la Recherche Scientifique - FNRS (Belgium; A.K.E.), and Fondation Simone et Pierre Clerdent (Belgium; A.K.E.). A.C.M. was supported by a doctoral fellowship from Fondation Française pour la Recherche Médicale (FRM: FDT20140930830). A.K.E. is a Research Director of the FRS–FNRS (Belgium) and a WELBIO investigator (Belgium). This work was also supported by the ATHOS Consortium, including the Fonds Unique Interministériel (FUI), the Région Alsace and our partners, Domain Therapeutics (Illkirch, France), and Prestwick Chemicals (Illkirch, France).
Funding
HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
16658HHS | NIH | National Institute on Drug Abuse (NIDA)
05010Canada Foundation for Innovation (CFI)
Canada Research Chairs (Chaires de recherche du Canada)
Fondation pour la Recherche Médicale (FRM)
FDT20140930830FRS-FNRS
Other Version
- You are viewing the most recent version of this article.
- previous version (July 25, 2019).
Article usage
In this issue
